GPhA Applauds Senate Passage of Supply Chain Safety Legislation

Published Online: Monday, November 18, 2013
Follow Pharmacy_Times:
PRESS RELEASE

WASHINGTON, DC, (November 18, 2013) — The Generic Pharmaceutical Association (GPhA) commends today’s Senate vote to pass the Drug Quality and Security Act (HR 3204), legislation that makes it easier to monitor drugs throughout the supply chain.

“Establishing a predictable, reliable national standard for electronic prescription medicine tracking further safeguards our nation’s prescription drug supply and protects patients,” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association. “This bipartisan bill is the culmination of years of hard work from Congress and stakeholders at every level of the supply chain. Modernizing the nation’s prescription drug tracking system enhances the ability of regulators to limit risks posed by counterfeit or adulterated products and reassures patients that the generic medicines they receive are secure from the manufacturer all the way to the pharmacy.”

The Drug Quality and Security Act replaces a patchwork of state laws with a uniform, consistent national standard for keeping accurate records of prescription medication. The bill requires manufacturers to put serial numbers on all medication containers within the next four years. In the next decade, electronic tracking codes are expected to monitor medication at the package level from manufacturer through to the pharmacy.

In particular, GPhA applauds Senate Health, Education, Labor and Pensions (HELP) Committee Chairman Sen. Tom Harkin (D-IA), Senate HELP Ranking Member Sen. Lamar Alexander (R-TN), Sen. Michael Bennet (D-CO), Sen. Richard Burr (R-NC), as well as House Energy and Commerce Committee Chairman Rep. Fred Upton (R-MI), House Energy and Commerce Ranking Member Rep. Henry Waxman (D-CA), Rep. Bob Latta (R-OH) and Rep. Jim Matheson (D-UT) for the years of hard work that culminated in the bipartisan passage of this legislation.

GPhA looks forward to the Drug Quality and Security Act reaching the desk of the President where it is expected to be signed into law. GPhA also supports electronic labeling provisions that remain under discussion and encourages continued efforts to finalize the proposed rule on e-labeling.
Related Articles
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
“The Generic Pharmaceutical Association (GPhA) is deeply disappointed in today’s 21st Century Cures discussion draft. While we appreciate that it is a draft, in its current form, the bill would upset the important balance between creating competition and encouraging innovation in the pharmaceutical marketplace, putting savings at risk and limiting access to affordable medicines for millions of American patients.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$